Total
0
Shares
Noxopharm (ASX:NOX) - Executive Chairman & CEO, Graham Kelly - The Market Herald
Executive Chairman & CEO, Graham Kelly
Source: Switzer Financial Group
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • Australian drug developer Noxopharm (NOX) has entered a trading halt this morning as it prepares for an upcoming capital raise
  • Currently, it is unknown how much the company is aiming to raise and what it will use the funds for
  • The trading halt means company shares will be paused until Thursday, December 3, or when more details about the raise are announced
  • Last month, Noxopharm's DARRT cancer treatment was validated by a U.S. university group
  • On the market, Noxopharm last traded at 64 cents per share on November 30

Noxopharm (NOX) has entered a trading halt ahead of an upcoming capital raise.

So far, it is unknown how much the company is aiming to raise and where the funds will be spent.

Noxopharm is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock.

Company shares will be paused from trade until Thursday, December 3, or when more details about the raise are released to the market.

Last month, the company said a recent discovery by a U.S. university group has validated its DARRT cancer treatment program.

The university has been researching the elusive phenomenon abscopal response, which is when radiation shrinks the tumour and the body of the tumour.

Noxopharm said the phase two research for this study will begin early next year.

For the September quarter, the company burnt through $3.3 million on operating activities, with the majority of capital spent on research and development. At the end of the period, Noxopharm had nearly $4 million in the bank.

On the market, Noxopharm last traded at 64 cents per share on November 30.

NOX by the numbers
More From The Market Herald
Credit Intelligence (ASX:CI1) - Managing Director & CEO, Jimmie Wong - The Market Herald

" Credit Intelligence (ASX:CI1) enters trading halt ahead of capital raise

Fintech company Credit Intelligence (CI1) has placed its shares in a trading halt ahead of an upcoming capital raise.
ioneer (ASX:INR) - Managing Director, Bernard Rowe - The Market Herald

" ioneer (ASX:INR) enters trading halt ahead of capital raise

ioneer (INR) has entered into a trading halt ahead of an upcoming capital raise.
Kula Gold (ASX:KGD) to begin drilling at Airfield next week

" Kula Gold (ASX:KGD) enters trading halt, plans capital raise

Kula Gold (KGD) has entered a trading halt for the purpose of considering, planning and executing a capital raising.
New World Resources (ASX:NWC) set to raise $10M for Antler

" Whispir (ASX:WSP) ends Monday in trading halt

Whispir (WSP) has entered a trading halt at the end of Monday’s trading session as it gets ready to raise more capital.